Research shows both compounds can promote blood vessel formation, faster recovery, and reduced inflammation in lab settings
Finally, poor oral bioavailability, incomplete toxicology, uncertain long-term effects, and the absence of controlled human trials remain major limitations
Peptide Therapies (BPC-157) BPC-157 is a synthetic peptide marketed online as an injury-healing solution
Research Evidence Context Published human GHK-Cu research has primarily evaluated topical and wound-care formulations [1] [2] [3] [4] [5] , while local administration in an animal wound model provides additional preclinical context [6]
Researchers use it in laboratory studies of fat metabolism under controlled conditions
GLP-1 pharma giants Eli Lilly and Novo Nordisk slapped some of them with lawsuits